The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Open accessPublished version of a preprint
Abstract
The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern that waning immunity may predispose to reinfection. We analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at 6 months following infection. T cell responses were present by ELISPOT and/or intracellular cytokine staining analysis in all donors and characterized by predominant CD4+ T cell responses with strong interleukin (IL)-2 cytokine expression. Median T cell responses were 50% higher in donors who had experienced a symptomatic infection, indicating that the severity of primary infection establishes a 'set point' for cellular immunity. T cell responses to spike and nucleoprotein/membrane proteins were correlated with peak antibody levels. Furthermore, higher levels of nucleoprotein-specific T cells were associated with preservation of nucleoprotein-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T cell responses are retained at 6 months following infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using HLA class I and II predicted peptide “megapools,” circulating SARS-CoV-2-specific CD8+ and CD4+ T cells were identified in COVID-19 acute, mild and convalescent patients [110, 118-125].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [124]
Experimental — accuracy not yet measuredIn the citing paper
“documented examples of SARS-CoV-2 reinfection as well as evidence of short-lived immunity to endemic human coronavirus (hCoV) infections raise the prospect that protective immunity after SARS-CoV-2 infection may last for months instead of years.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [10]
In the citing paper
“Cellular responses to infection seem to be generally more stable3,8,10 (Fig. 1) but their role in immune protection is not yet clear”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · cited 2×
“IFN-g responses are broadly equivalent to IL2 at early time points after infection (24) but the profile at 6 months suggests that the relative proportion of Th1 effector cells decreases over time or they revert to central memory state (25).”
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
T-cell quality in memory and protection: implications for vaccine design
Seder, R. A., Darrah, P. A., & Roederer, M. (2008) · Nature reviews. Immunology · doi:10.1038/nri2274 · Cited by 1,565
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Viral Load Dynamics and Clinical Disease Severity in Patients with SARS-CoV-2 Infection
Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,479
Cited by
Sorted by citations
Items 101–200 of 392
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition
Tye, E. X. C., Jinks, E., Haigh, T. A., Kaul, B., Patel, P., Parry, H., Newby, M. L., Crispin, M., Kaur, N., Moss, P. A. H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01351-7 · Cited by 37
Self-citationAntigen presentation in SARS-CoV-2 infection: the role of class I HLA and ERAP polymorphisms
Saulle, I., Vicentini, C., Clerici, M., & Biasin, M. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.05.003 · Cited by 32
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk, P., Pimentel, V. O., Emmelot, M. E., Poelen, M. C. M., Çevirgel, A., Schepp, R. M., den Hartog, G., Reukers, D. F. M., Beckers, L., van Beek, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817876 · Cited by 32
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID
Krishna, B. A., Lim, E. Y., Mactavous, L., Lyons, P., Döffinger, R., Bradley, J. R., Smith, K. G. C., Sinclair, J. H., Matheson, N. J., Lehner, P. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104129 · Cited by 32
Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Charland, N., Trépanier, S., et al. (2021) · medRxiv · doi:10.1101/2021.05.14.21257248 · Cited by 33
Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1996 · Cited by 34
Shayak, B., Sharma, M., Gaur, M., & Mishra, A. K. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.018 · Cited by 31
Salzer, R., Clark, J. J., Vaysburd, M., Chang, V. T.-C., Albecka, A., Kiss, L., Sharma, P., Llamazares, A. G., Kipar, A., Hiscox, J. A., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14171 · Cited by 31
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31
Jeong, S., Heo, Y., Jeong, J.-H., Ham, S.-J., Yum, J. S., Ahn, B.-C., Song, C., & Chun, E. (2021) · Vaccines · doi:10.3390/vaccines9090957 · Cited by 29
Niesen, M. J. M., Anand, P., Silvert, E., Suratekar, R., Pawlowski, C., Ghosh, P., Lenehan, P. J., Hughes, T. K., Zemmour, D., O’Horo, J. C., et al. (2021) · medRxiv · doi:10.1101/2021.07.01.21259833 · Cited by 29
Bruminhent, J., Setthaudom, C., Chaumdee, P., Boongird, S., Kiertiburanakul, S., Malathum, K., Nongnuch, A., Phuphuakrat, A., Jirasiritham, S., Janphram, C., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16867 · Cited by 28
Binayke, A., Zaheer, A., Vishwakarma, S., Singh, S., Sharma, P., Chandwaskar, R., Gosain, M., Raghavan, S., Murugesan, D. R., Kshetrapal, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00794-9 · Cited by 28
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29
Capra, A. P., Ardizzone, A., Pantò, G., Paterniti, I., Campolo, M., Crupi, L., Squeri, R., & Esposito, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043537 · Cited by 28
Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
Mohan, A., Iyer, V. A., Kumar, D., Batra, L., & Dahiya, P. (2023) · Life · doi:10.3390/life13112121 · Cited by 31
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
Ivanova, E. N., Shwetar, J., Devlin, J. C., Buus, T. B., Gray-Gaillard, S. L., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Mimitou, E. P., et al. (2021) · medRxiv · doi:10.1101/2021.04.20.21255677 · Cited by 29
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects
Gallerani, E., Proietto, D., Dallan, B., Campagnaro, M., Pacifico, S., Albanese, V., Marzola, E., Marconi, P., Caputo, A., Appay, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693054 · Cited by 28
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
Titov, A., Shaikhutdinova, R., Shcherbakova, O. V., Serdyuk, Y. V., Sheetikov, S. A., Zornikova, K. V., Maleeva, A. V., Khmelevskaya, A. A., Dianov, D. V., Shakirova, N. T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157699 · Cited by 26
Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives
Benucci, M., Infantino, M. G., Marotto, D., Ardizzone, S., Manfredi, M., & Sarzi‐Puttini, P. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/7afn90 · Cited by 25
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31
Scurr, M. J., Zelek, W. M., Lippiatt, G., Somerville, M. S., Burnell, S. E. A., Capitani, L., Davies, K., Lawton, H., Tozer, T., Rees, T., et al. (2021) · Immunology · doi:10.1111/imm.13433 · Cited by 24
Li, L., Müftüoğlu, M., Liang, S., Basyal, M., Lv, J., Akdogan, M. E., Chen, K., Andreeff, M., Flowers, C. R., & Parmar, S. (2022) · JCI Insight · doi:10.1172/jci.insight.156559 · Cited by 24
Bruminhent, J., Setthaudom, C., Kitpermkiat, R., Kiertiburanakul, S., Malathum, K., Assanatham, M., Nongnuch, A., Phuphuakrat, A., Chaumdee, P., Janphram, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07574-w · Cited by 25
Tut, G., Lancaster, T., Sylla, P., Butler, M. S., Kaur, N., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00118-0 · Cited by 23
Self-citationPrevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults
Samandari, T., Ongalo, J., McCarthy, K. D., Biegon, R., Madiega, P. A., Mithika, A., Orinda, J., Mboya, G., Mwaura, P., Anzala, O. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170011 · Cited by 24
Dutt, T. S., LaVergne, S. M., Webb, T. L., Baxter, B. A., Stromberg, S., McFann, K., Berry, K., Tipton, M., Alnachoukati, O., Zier, L., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100830 · Cited by 24
Jantarabenjakul, W., Sodsai, P., Chantasrisawad, N., Jitsatja, A., Ninwattana, S., Thippamom, N., Ruenjaiman, V., Tan, C. W., Pradit, R., Sophonphan, J., et al. (2022) · Vaccines · doi:10.3390/vaccines10050639 · Cited by 24
Grebe, E., Stone, M., Spencer, B. R., Akinseye, A., Wright, D. J., Germanio, C. D., Bruhn, R. L., Zurita, K. G., Contestable, P., Green, V., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3008.240659 · Cited by 24
Immunity after SARS-CoV-2 infections
Jagannathan, P., & Wang, T. T. (2021) · Nature Immunology · doi:10.1038/s41590-021-00923-3 · Cited by 22
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25
Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., Holubar, M. K., et al. (2022) · eLife · doi:10.7554/elife.77943 · Cited by 30
Islam, M. S., Wang, Z., Abdel‐Mohsen, M., Chen, X., & Montaner, L. J. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiac001 · Cited by 23
Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature
Tsagkli, P., Geropeppa, M., Papadatou, I., & Spoulou, V. I. (2024) · Vaccines · doi:10.3390/vaccines12091051 · Cited by 24
Saxena, A., Guttmann, A., Masson, M., Kim, M., Haberman, R. H., Castillo, R., Scher, J. U., Deonaraine, K., Engel, A., Belmont, M. H., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00114-4 · Cited by 23
Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing
Zhao, P., Zou, J., Zhou, F., Zhu, Y., Song, Q., Yu, D., & Li, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108767 · Cited by 21
Nam, M., Yun, S. G., Kim, S., Kim, C. G., Cha, J. H., Lee, C., Kang, S., Park, S. G., Kim, S. B., Lee, K.-B., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02495-21 · Cited by 20
A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Wu, N., Zhang, J., Shen, Y., Zhang, X., Zhou, J., Wu, Y., Li, E., Meng, X., Chuai, X., Chiu, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.011 · Cited by 22
Favà, A., Donadeu, L., Jouvé, T., González‐Costello, J., Lladó, L., Santana, C., Toapanta, N., Comabella, M., Pernin, V., Facundo, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2021.12.029 · Cited by 21
Phenotypes and Functions of SARS-CoV-2-Reactive T Cells
Jung, M. K., & Shin, E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0079 · Cited by 19
Immune response induced by novel coronavirus infection
Sun, Y., Zou, Y., Wang, H., Cui, G., Yu, Z., & Ren, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.988604 · Cited by 20
Vulpis, E., Giulimondi, F., Digiacomo, L., Zingoni, A., Safavi‐Sohi, R., Sharifi, S., Caracciolo, G., & Mahmoudi, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00291 · Cited by 21
Angelis, M. L. D., Francescangeli, F., Rossi, R., Giuliani, A., Maria, R. D., & Zeuner, A. (2021) · Viruses · doi:10.3390/v13060961 · Cited by 17
Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
Borena, W., Bánki, Z., Bates, K., Winner, H., Riepler, L., Rössler, A., Pipperger, L., Theurl, I., Falkensammer, B., Ulmer, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103534 · Cited by 18
Vo, H. T. M., Maestri, A., Auerswald, H., Sorn, S., Lay, S., Seng, H., Sann, S., Ya, N., Pean, P., Dussart, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817905 · Cited by 19
Chevaisrakul, P., Lumjiaktase, P., Kietdumrongwong, P., Chuatrisorn, I., Chatsangjaroen, P., & Phanuphak, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-28101-5 · Cited by 18
Delay-differential SEIR modeling for improved modelling of infection dynamics
Kiselev, I. N., Akberdin, I. R., & Kolpakov, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-40008-9 · Cited by 33
Yang, G., Cao, J., Qin, J., Mei, X., Deng, S., Xia, Y., Zhao, J., Wang, J., Luan, T., Chen, D., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01867-4 · Cited by 20
Ma, T., Ryu, H., McGregor, M. M., Babcock, B. R., Neidleman, J. A., Xie, G., George, A. F., Frouard, J., Murray, V., Gill, G., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100465 · Cited by 19
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 18
Johnson, S. A., Phillips, E., Adele, S., Longet, S., Malone, T., Mason, C. J., Stafford, L., Jämsén, A., Gardiner, S., Deeks, A. S., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad027 · Cited by 18
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 20
Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response
Zornikova, K. V., Khmelevskaya, A. A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., & Efimov, G. A. (2022) · Communications Biology · doi:10.1038/s42003-022-04250-7 · Cited by 17
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2
Jin, X., Liu, X. K., & Shen, C. (2022) · Virus Research · doi:10.1016/j.virusres.2022.199024 · Cited by 18
Tapela, K., Prah, D. A., Tetteh, B. E., Nuokpem, F. Y., Dosoo, D., Coker, A., Kumi-Ansah, F., Amoako, E. F., Assah, K. O., Kilba, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114533 · Cited by 17
Li, J., Wu, J., Long, Q., Wu, Y., Hu, X., He, Y., Jiang, M., Li, J., Zhao, L., Yang, S., et al. (2022) · Research · doi:10.34133/2022/9873831 · Cited by 15
Ngalamika, O., Lidenge, S. J., Mukasine, M. C., Kawimbe, M., Kamanzi, P., Ngowi, J. R., Mwaiselage, J. D., & Tso, F. Y. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.009 · Cited by 16
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses
Akanmu, S. A., Herrera, B. B., Chaplin, B., Ogunsola, S., Osibogun, A. O., Onawoga, F., John‐Olabode, S., Akase, I. E., Nwosu, A. O., Hamel, D. J., et al. (2023) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2023.100156 · Cited by 14
Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus InfectionPreprint
Ivanova, E. N., Devlin, J. C., Buus, T. B., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Zhang, C., Desvignes, L., Ødum, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3838993 · Cited by 14
Speletas, M. G., Voulgaridi, I., Sarrou, S., Dadouli, K., Mouchtouri, V. Α., Nikoulis, D. J., Tsakona, M., Kyritsi, M. A., Peristeri, A.-M., Avakian, I., et al. (2022) · Vaccines · doi:10.3390/vaccines10020316 · Cited by 15
SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients
Onyango, T. B., Zhou, F., Bredholt, G., Brokstad, K. A., Lartey, S. L., Mohn, K. G.-I., Özgümüş, T., Kittang, B. R., Linchausen, D. W., Shafiani, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1287388 · Cited by 14
Smith, I., Callum, G. J. M., Sabljic, A. V., Marfía, J. I., Bombicino, S. S., Trabucchi, A., Iacono, R. F., Birenbaum, J. M., Vázquez, S., Minoia, J. M., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27889 · Cited by 15
Boongird, S., Chuengsaman, P., Setthaudom, C., Nongnuch, A., Assanatham, M., Phanprasert, S., Kitpermkiat, R., Kiertiburanakul, S., Malathum, K., Phuphuakrat, A., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00574-9 · Cited by 15
Sachak-Patwa, R., Byrne, H. M., Dyson, L., & Thompson, R. N. (2021) · Communications Medicine · doi:10.1038/s43856-021-00038-8 · Cited by 13
Matsumoto, A., Hara, M., Ashenagar, M. S., Tokiya, M., Sawada, T., Iwasaka, C., Furukawa, T., Kitagawa, K., Miyake, Y., & Hirota, Y. (2022) · Vaccines · doi:10.3390/vaccines10071035 · Cited by 14
Poteryaev, D. A., Abbasova, S. G., Ignatyeva, P. E., Strizhakova, O. M., Колесник, С. В., & Авгатович, Х. Р. (2021) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2021-21-3-178-192 · Cited by 15
Barrios, Y., Franco, A., Sánchez‐Machín, I., Guedes, P. P., González‐Pérez, R., & Matheu, V. M. (2021) · Vaccines · doi:10.3390/vaccines9060575 · Cited by 13
A T cell–based SARS-CoV-2 spike protein vaccine provides protection without antibodies
Shi, J., Zheng, J. H., Zhang, X., Tai, W., Compas, R., Deno, J., Jachym, N., Verma, A. K., Wang, G., Guan, X., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.155789 · Cited by 13
T and B cell responses in different immunization scenarios for COVID-19: a narrative review
Mortari, E. P., Ferrucci, F., Zografaki, I., Carsetti, R., & Pacelli, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535014 · Cited by 14
Parry, H., Bruton, R. K., Ayodele, R., Sylla, P., McIlroy, G., Logan, N. A., Scott, S., Nicol, S., Verma, K., Stephens, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100739 · Cited by 12
Self-citationBamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
Ramirez, S. I., Grifoni, A., Weiskopf, D., Parikh, U. M., Heaps, A., Faraji, F., Sieg, S. F., Ritz, J., Moser, C., Eron, J. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.163471 · Cited by 11
Ireland, G., Jeffery-Smith, A., Zambon, M. C. F. A., Höschler, K., Harris, R., Poh, J., Baawuah, F., Beckmann, J., Okike, I. O., Ahmad, S. S. Y., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101150 · Cited by 11
Self-citationAgallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 12
Highly conserved Betacoronavirus sequences are broadly recognized by human T cells
Neto, T. A. P., Zmasek, C. M., Avalos, L., Sidney, J., Trevizani, R., Phillips, E. J., Mallal, S. A., Frazier, A., Tan, G. S., Scheuermann, R. H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.015 · Cited by 13
Fischer, B., Lindenkamp, C., Lichtenberg, C., Birschmann, I., Knabbe, C., & Hendig, D. (2021) · Life · doi:10.3390/life11080805 · Cited by 12
Konik, M., Lindemann, M., Zettler, M., Meller, L., Dolff, S., Rebmann, V., Horn, P. A., Dittmer, U., Krawczyk, A., Schipper, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194606 · Cited by 13
Natalini, A., Simonetti, S., Sher, C., D’Oro, U., Hayday, A., & Rosa, F. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214367 · Cited by 12
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13
A Closer Look into FDA-EUA Approved Diagnostic Techniques of Covid-19
Oh, H.-J., Ahn, H., & Tripathi, A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00268 · Cited by 11
Kumar, S., Saxena, S. K., Maurya, V. K., & Tripathi, A. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.804808 · Cited by 12
Kittikraisak, W., Hunsawong, T., Punjasamanvong, S., Wongrapee, T., Suttha, P., Piyaraj, P., Leepiyasakulchai, C., Tanathitikorn, C., Yoocharoen, P., Jones, A. R., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12975 · Cited by 11
Kowalski, E., Stengel, A., Schneider, A., Goebel‐Stengel, M., Zipfel, S., & Graf, J. (2022) · Vaccines · doi:10.3390/vaccines10030455 · Cited by 11
Costiniuk, C. T., Singer, J., Langlois, M., Kulić, I., Needham, J., Burchell, A. N., Jenabian, M.-A., Walmsley, S. L., Ostrowski, M., Kovacs, C. M., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-054208 · Cited by 11
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-309746/v1 · Cited by 12
Samaan, P., Korosec, C. S., Budylowski, P., Chau, S., Pasculescu, A., Qi, F., Delgado-Brand, M., Tursun, T. R., Mailhot, G., Dayam, R. M., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01685-24 · Cited by 11
An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses
Lin, H., Zhang, J., Dong, S., Liu, Y., Liu, P., Gao, G. F., Liu, W. J., & Wu, G. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.04.005 · Cited by 10
Al‐Rifai, R. H., Hosani, F. I. A., Abuyadek, R. M., Atef, S. H., Donnelly, J. G., Leinberger‐Jabari, A., Ahmed, L. A., Altrabulsi, B., Alatoom, A. A., Alsuwaidi, A. R., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1092646 · Cited by 10
Lochmanová, A., Martínek, J., Tomášková, H., Zelená, H., Dieckmann, K., Grage‐Griebenow, E., Ježo, E., & Janošek, J. (2023) · Diagnostics · doi:10.3390/diagnostics13040637 · Cited by 10
Abdelaziz, M. O., Raftery, M. J., Weihs, J., Bielawski, O., Edel, R., Köppke, J. K. C., Vladimirova, D., Adler, J. M., Firsching, T. C., Voß, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166765 · Cited by 10
Gómez‐Carballa, A., Barral‐Arca, R., Cebey‐López, M., Currás-Tuala, M. J., Pischedda, S., Rial, J. G., Habgood-Coote, D., Herberg, J. A., Kaforou, M., Martinón‐Torres, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580219 · Cited by 10
Maggi, E., Azzarone, B. G., Canonica, G. W., & Moretta, L. (2021) · Allergy · doi:10.1111/all.15112 · Cited by 9
A novel geo-hierarchical population mobility model for spatial spreading of resurgent epidemics
Topîrceanu, A., & Precup, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-93810-8 · Cited by 11
Brunk, F., Moritz, A., Nelde, A., Bilich, T., Casadei, N., Fraschka, S. A. K., Heitmann, J. S., Hörber, S., Peter, A., Rammensee, H., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149290 · Cited by 10
Pérez‐Cabezas, B., Ribeiro, R. J. T., Costa, I., Esteves, S., Teixeira, A. R., Reis, T., Monteiro, R., Afonso, A., Pinheiro, V. C. A., Antunes, M. I., et al. (2021) · medRxiv · doi:10.1101/2021.01.04.20248897 · Cited by 11
A Delay Differential Equation approach to model the COVID-19 pandemicPreprint
Kiselev, I. N., Akberdin, I. R., & Kolpakov, F. (2021) · medRxiv · doi:10.1101/2021.09.01.21263002 · Cited by 10
Montgomery, L. C., & Larbi, A. (2025) · Vaccines · doi:10.3390/vaccines13040420 · Cited by 9
Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients
Guerrera, G., Mandelli, A., Finardi, A., Orrico, M., D’Orso, S., Picozza, M., Noviello, M., Beretta, V., Bonetti, B., Calabrese, M., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221102158 · Cited by 10
Metadata
- Authors
- Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., Taylor, S., Hewson, J., Hallis, B., Stapley, L., Borrow, R., Linley, E., Ahmad, S., Parker, B., Horsley, A., Amirthalingam, G., Brown, K., Ramsay, M. E., Ladhani, S., & Moss, P.
- Affiliations
- University of Birmingham (GB)
- Manchester Royal Infirmary (GB)
- Manchester Academic Health Science Centre (GB)
- Manchester University NHS Foundation Trust (GB)
- University of Manchester (GB)
- St George's, University of London (GB)
- Corresponding author
- Ladhani, Shamez
- Moss, Paul
- ORCID
- Venue
- Nature Immunology
- Published
- 2021-03-05
- Volume
- 22
- Issue
- 5
- Pages
- 620-626
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC7610739
- OpenAlex
- W3134099704
- Cited by
- 392
- References
- 39
- Citations by year
- 2026: 10 · 2025: 31 · 2024: 37 · 2023: 56 · 2022: 115 · 2021: 137
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-05-20)
- Open access
- bronze
- doi.org
- Locations
- Nature Immunology (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion, cc-by-nd)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- RCUK | Medical Research Council (MR/R011230/1)
- Bloodwise (17009)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV-2, COVID-19 pandemic, T cell immunity, CD4+ T cells, waning immunity, reinfection, interleukin-2, spike protein, nucleocapsid protein, membrane proteins, antibody kinetics, symptomatic infection, set point
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Antigens, Viral, Female, Humans, Immunity, Cellular, Interleukin-2, Male, Middle Aged, Phenotype, Time Factors, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Host-Pathogen Interactions, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
